Transient receptor potential (TRP) channels, promising potential diagnostic and therapeutic tools for cancer

BioScience Trends

Volumn 8, Issue 1, 2014, Pages 1-10

  Chen, Jianpeng ^a   Luan, Yi ^b   Yu, Ruofei ^c   Zhang, Zheng ^a   Zhang, Jinbiao ^d   Wang, Weibo ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b Shandong Center for Disease Control Prevention   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d The Endovascular Interventional Treatment Center of Chinese Peoples Liberation Army   (China)

Author keywords

Cancer; Ion channels; Migration; Proliferation; Transient receptor potential (TRP)

Indexed keywords

CALCIUM; DIAGNOSTIC AGENT; SODIUM; TRANSIENT RECEPTOR POTENTIAL CHANNEL;

CELL MOTION; CELL PROLIFERATION; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW;

CALCIUM; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; NEOPLASMS; SODIUM; TRANSIENT RECEPTOR POTENTIAL CHANNELS;

EID: 84896876536     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.8.1     Document Type: Review

References (86)

1. Huber, SM. Oncochannels. Cell Calcium. 2013; 53:241-255.
2. Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE, Hall DM. Molecular interactions in cancer cell metastasis. Acta Histochem. 2010; 112:3-25.
3. Bidaux G, Roudbaraki M, Merle C, Crépin A, Delcourt P, Slomianny C, Thebault S, Bonnal JL, Benahmed M, Cabon F, Mauroy B, Prevarskaya N. Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: Functional androgen receptor requirement. Endocr Relat Cancer. 2005; 12:367-382.
4. 2+ influx. Cell Calcium. 2010; 47:425-432.
5. Montell C, Rubin GM. Molecular characterization of the Drosophila trp locus: A putative integral membrane protein required for phototransduction. Neuron.1989; 2:1313-1323.
6. Pan Z, Yang H, Reinach PS. Transient receptor potential (TRP) gene superfamily encoding cation channels. Hum Genomics. 2011; 5:108.
7. Wu LJ, Sweet TB, Clapham DE. International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Pharmacol Rev. 2010; 62:381-404.
8. Gaudet R. TRP channels entering the structural era. J Physiol. 2008; 586:3565-3575.
9. Nilius B, Owsianik G. The transient receptor potential family of ion channels. Genome Biol. 2011; 12:218-228.
10. Tano JY, Lee RH, Vazquez G. Macrophage function in atherosclerosis: Potential roles of TRP channels. Channels. 2012; 6:141-148.
11. Sun Y, Shi YK. Handbook of Clinical Medical Oncology. People's Medical Publishing House, Beijing, China, 2007; pp. 388-403. (in Chinese)
12. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.
13. Ramalingam S, Belani CP. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol. 2004; 31:68-74.
14. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007; 18:317-323.
15. Tajeddine N, Gailly P. TRPC1 protein channel is major regulator of epidermal growth factor receptor signaling. J Biol Chem. 2012; 287:16146-16157.
16. Jiang HN, Zeng B, Zhang Y, Daskoulidou N, Fan H, Qu JM, Xu SZ. Involvement of TRPC channels in lung cancer cell differentiation and the correlation analysis in human non-small cell lung cancer. PLoS One. 2013; 8:e67637.
17. Saito H, Minamiya Y, Watanabe H, Takahashi N, Ito M, Toda H, Konno H, Mitsui M, Motoyama S, Ogawa J. Expression of the transient receptor potential channel C3 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. Ann Surg Oncol. 2011; 18:3377-3383.
18. Gao H, Chen X, Du X, Guan B, Liu Y, Zhang H. EGF enhances the migration of cancer cells by up-regulation of TRPM7. Cell Calcium. 2011; 50:559-568.
19. Knowlton WM, McKemy DD. TRPM8: From cold to cancer, peppermint to pain. Curr Pharm Biotechnol. 2011; 12:68-77.
20. Tsavaler L, Shapero MH, Morkowski S, Laus R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. 2001; 61:3760-3769.
21. Jiemin M, Ahmedin J. Breast Cancer Statistics. In: Breast Cancer Metastasis and Drug Resistance (Ahmad A, ed.). Springer, New York, USA, 2013; pp. 1-18.
22. Dhennin-Duthille I, Gautier M, Faouzi M, Guilbert A, Brevet M, Vaudry D, Ahidouch A, Sevestre H, Ouadid-Ahidouch H. High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: Correlation with pathological parameters. Cell Physiol. Biochem. 2011; 28:813-822.
23. EI Hiani Y, Lehen'kyi V, Ouadid-Ahidouch H, Ahidouch A. Activation of the calcium-sensing receptor by high calcium induced breast cancer cell proliferation and TRPC1 cation channel over-expression potentially through EGFR pathways. Arch Biochem Biophys. 2009; 486:58-63.
24. 2+ influx. J Biol Chem. 2005; 280:12908-12916.
25. Aydar E, Yeo S, Djamgoz M, Palmer C. Abnormal expression, localization and interaction of canonical transient re-ceptor potential ion channels in human breast cancer cell lines and tissues: A potential target for breast cancer diagnosis and therapy. Cancer Cell Int. 2009; 9:23.
26. Bolanz KA, Hediger MA, Landowski CP. The role of TRPV6 in breast carcinogenesis. Mol Cancer Ther. 2008; 7:271-279.
27. Guilbert A, Gautier M, Dhennin-Duthille I, Haren N, Sevestre H, Ouadid-Ahidouch H. Evidence that TRPM7 is required for breast cancer cell proliferation. Am J Physiol Cell Physiol. 2009; 297:C493-502.
28. Clark K, Middelbeek J, Lasonder E. TRPM7 regulates myosin-IIA filament stability and protein localization by heavy chain phosphorylation. J Mol Biol. 2008; 378:788-801.
29. Meng X, Cai C, Wu J. TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway. Cancer Lett. 2013; 333:96-102.
30. Quadid-Ahidouch H, Dhennin-Duthille I, Gautier M, Sevestre H, Ahidouch A. TRP calcium channel and breast cancer: Expression, role and correlation with clinical parameters. Bull Cancer. 2012; 99:655-664.
31. Chodon D, Guilbert A, Dhennin-Duthille I, Gautier M, Telliez MS, Sevestre H, Ouadid-Ahidouch H. Estrogen regulation of TRPM8 expression in breast cancer cells. BMC Cancer. 2010; 10:212.
32. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: What do they suggest? Epidemiol Rev. 2001; 23:3-13.
33. 2+/NFAT-dependent pathways. Oncogene. 2007; 26:7380-7385.
34. Zhao XZ, Guo HQ, Liu GX. Inhibitory effect of TRPV6 silencing on prostate cancer cell line LNCaP in vitro. Zhonghua Nan Ke Xue. 2010; 16:423-427. (in Chinese with English abstract)
35. 2+-selective cation channel TRPV6 in human prostate cancer: A novel prognostic marker for tumor progression. Oncogene. 2003; 22:7858-7861.
36. Zhang L and Barritt GJ. TRPM8 in prostate cancer cells: A potential diagnostic and prognostic marker with a secretory function? Endocr Relat Cancer. 2006; 13:27-38.
37. Fuessel S, Sickert D, Meye A, Klenk U, Schmidt U, Schmitz M, Rost AK, Weigle B, Kiessling A, Wirth MP. Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol. 2003; 23:221-228.
38. Bai VU, Murthy S, Chinnakannu K, Muhletaler F, Tejwani S, Barrack ER, Kim SH, Menon M, Veer Reddy GP. Androgen regulated TRPM8 expression: A potential mRNA marker for metastatic prostate cancer detection in body fluids. Int J Oncol. 2010; 36:443-450.
39. Henshall SM, Afar DE, Hiller J, et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003; 63:4196-4203.
40. Gkika D, Flourakis M, Lemonnier L and Prevarskaya N. PSA reduces prostate cancer cell motility by simulating TRPM8 activity and plasma membrane expression. Oncogene. 2010; 29:4611-4616.
41. Yue D, Wang Y, Xiao JY, Wang P, Ren CS. Expression of TRPC6 in benign and malignant human prostate tissues. Asian J Androl. 2009; 11:541-547.
42. Gabriella C, Varga A, Nyeste K, Marincsák R, Tóth BI, Kovács I, Kovács L, Bíró T. Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J Cancer Res Clin Oncol. 2009; 135:507-514.
43. Monet M, Lehen'kyi V, Gackiere F et al. Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Cancer Res. 2010; 70:1225-1235.
44. Henshall SM, Afar DE, Hiller J, et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003; 63:4196-203.
45. Zeng X, Sikka SC, Huang L, Sun C, Xu C, Jia D, Abdel-Mageed AB, Pottle JE, Taylor JT and Li M. Novel role for the transient receptor potential channel TRPM2 in prostate cancer cell proliferation. Prostate Cancer Prostatic Dis. 2009; 13:195-201.
46. Zhang W, Chu X, Tong Q, Cheung JY, Conrad K, Masker K, Miller BA. A novel TRPM2 isoform inhibits calcium influx and susceptibility to cell death. J Biol Chem. 2003; 278:16222-16229.
47. Kisielewski R, Tolwinska A, Mazurek A, Laudanski P. Inflammation and ovarian cancer-current views. Ginekol Pol. 2013; 84:293-297.
48. Yang SL, Cao Q, Zhou KC, Feng YJ, Wang YZ. Transient receptor potential channel C3 contributes to the progression of human ovarian cancer. Oncogene. 2009; 28:1320-1328.
49. Zeng B, Yuan C, Yang X, Atkin SL, Xu SZ. TRPC Channels and their splice variants are essential for promoting human ovarian cancer cell proliferation and tumorigenesis. Curr Cancer Drug Targets. 2013; 13:103-116.
50. Jemal A, Center MM, DeSantis C, Ward EM. Global Patterns of Cancer Incidence and Mortality Rates and Trends. Cancer Epidemiol Biomarkers Prev. 2010; 19:1893-1907.
51. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006; 12:17-20.
52. Verdecchia A, Corazziari I, Gatta G, Lisi D, Faivre J, Forman D. Explaining gastric cancer survival differences among European countries. Int J Cancer. 2004; 109:737-741.
53. Cai R, Ding X, Zhou K, Shi Y, Ge R, Ren G, Jin Y, Wang Y. Blockade of TRPC6 channels induced G2/M phase arrest and suppressed growth in human gastric cancer cells. Int J Cancer. 2009; 125:2281-2287.
54. Kim BJ, Park EJ, Lee JH, Jeon JH, Kim SJ, So I. Suppression of transient receptor potential melastatin 7 channel induces cell death in gastric cancer. Cancer Sci. 2008; 99:2502-2509.
55. Kim BJ, Nah SY, Jeon JH, So I, Kim SJ. Transient Receptor Potential Melastatin 7 Channels are Involved in Ginsenoside Rg3-Induced Apoptosis in Gastric Cancer Cells. Basic Clin Pharmacol Toxicol. 2011; 109:233-239.
56. Kim BJ, Kim SY, Lee S, Jeon JH, Matsui H, Kwon YK, Kim SJ, So I. The role of transient receptor potential channel blockers in human gastric cancer cell viability. Can J Physiol Pharmacol. 2012; 90:175-186.
57. Chow J, Norng M, Zhang J, Chai J. TRPV6 mediates capsaicin-induced apoptosis in gastric cancer cells-Mechanisms behind a possible new "hot" cancer treatment. Biochim Biophys Acta. 2007; 1773:565-576.
58. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893-2917.
59. Chen JG, Zhang SW. Liver cancer epidemic in China: Past, present and future. Semin Cancer Biol. 2011; 21:59-69.
60. Reuber MD. Transplantable Bile-Secreting Hepatocellular Carcinoma in the Rat. J Natl Cancer Inst. 1961; 26:891-899.
61. El Boustany C, Bidaux G, Enfissi A, Delcourt P, Prevarskaya N, Capiod T. Capacitative calcium entry and transient receptor potential canonical 6 expression control human hepatoma cell proliferation. Hepatology. 2008; 47:2068-2077.
62. Rychkov GY, Barritt GJ. Expression and Function of TRP Channels in Liver Cells. Adv Exp Med Biol. 2011; 704:667-686.
63. 2+ current in rat liver cells. Biochem J. 2005; 385:551-556.
64. Liu G, Xie C, Sun F, et al. Clinical significance of transient receptor potential vanilloid 2 expression in human hepatocellular carcinoma. Cancer Genet Cytogenet. 2010; 197:54-59.
65. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol. 2002; 12:421-429.
66. Chien CR, Lin HW, Yang CH, Yang SN, Wang YC, Kuo YC, Chen SW, Liang JA. High case volume of radiation oncologists is associated with better survival of nasopharyngeal carcinoma patients treated with radiotherapy: A multifactorial cohort analysis. Clin Otolaryngol. 2011; 36:558-565.
67. Kong F, Cai BZ, Chen XZ, Zhang J, Wang YM. Prognostic factors for survival of patients with nasopharyngeal carcinoma following conventional fractionation radiotherapy. Exp Ther Med. 2013; 6:57-60.
68. Wei C, Wang X, Chen M, Ouyang K, Song LS, Cheng H. Calcium flickers steer cell migration. Nature. 2008; 457:901-905.
69. Jiang J, Li MH, Inoue K, Chu XP, Seeds J, Xiong ZG. Transient receptor potential melastatin 7-like current in human head and neck carcinoma cells: Role in cell proliferation. Cancer Res. 2007; 67:10929-10938.
70. He B, Liu F, Ruan J, Li A, Chen J, Li R, Shen J, Zheng D, Luo R. Silencing TRPC1 expression inhibits invasion of CNE2 nasopharyngeal tumor cells. Oncol Rep. 2012; 5:1548-1554.
71. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006; 2:494-503.
72. Ahluwalia MS, Gladson CL. Progress on antiangiogenic therapy for patients with malignant glioma. J Oncol. 2010; 2010:689018.
73. Bomben VC, Turner KL, Barclay TT, Sontheimer H. Transient receptor potential canonical channels are essential for chemotactic migration of human malignant gliomas. J Cell Physiol. 2011; 226:1879-1888.
74. Ding X, He Z, Zhou K, Cheng J, Yao H, Lu D, Cai R, Jin Y, Dong B, Xu Y, Wang Y. Essential Role of TRPC6 Channels in G2/M Phase Transition and Development of Human Glioma. J Natl Cancer Inst. 2010; 102:1052-1068.
75. Amantini C, Mosca M, Nabissi M, Lucciarini R, Caprodossi S, Arcella A, Giangaspero F, Santoni G. Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J Neurochem. 2007; 102:977-990.
76. Nabissi M, Morelli MB, Amantini C, Farfariello V, Ricci-Vitiani L, Caprodossi S, Arcella A, Santoni M, Giangaspero F, De Maria R, Santoni G. TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. Carcinogenesis. 2010; 31:794-803.
77. Jones V, Katiyar SK. Emerging phytochemicals for prevention of melanoma invasion. Cancer Lett. 2013; 335:251-258.
78. Markovic SN, Erickson LA, Rao RD, et al. Malignant melanoma in the 21st century, part 1: Epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007; 82:364-380.
79. Duncan LM, Deeds J, Hunter J, Shao J, Holmgren LM, Woolf EA, Tepper RI, Shyjan AW. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res. 1998; 58:1515-1520.
80. Fang D, Setaluri V. Expression and up-regulation of alternatively spliced transcripts of melastatin, a melanoma metastasis-related gene, in human melanoma cells. Biochem Biophys Res Commun. 2000; 279:53-61.
81. Deeds J, Cronin F, Duncan LM. Patterns of melastatin mRNA expression in melanocytic tumors. Hum Pathol. 2000; 31:1346-1356.
82. Duncan LM, Deeds J, Cronin FE, et al. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol. 2001; 19:568-576.
83. Miller AJ, Du J, Rowan S, Hershey CL, Widlund HR, Fisher DE. Transcriptional Regulation of the Melanoma Prognostic Marker Melastatin (TRPM1) by MITF in Melanocytes and Melanoma. Cancer Res. 2004; 64:509-516.
84. Yamamura H, Ugawa S, Ueda T, Morita A, Shimada S. TRPM8 activation suppresses cellular viability in human melanoma. Am J Physiol Cell Physiol. 2008; 295:C296-301.
85. Naziroglu M. TRPM2 cation channels, oxidative stress and neurological diseases: Where are we now? Neurochem Res. 2011; 36:355-366.
86. McNeill MS, Paulsen J, Bonde G, Burnight E, Hsu MY, Cornell RA. Cell death of melanophores in zebrafish trpm7 mutant embryos depends on melanin synthesis. J Invest Dermatol. 2007; 127:2020-2030.